Actively Recruiting

Age: 18Years - 75Years
All Genders
NCT03158090

The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research

Led by Ginkgo Leaf Center for Rare Disorders · Updated on 2022-03-16

1965

Participants Needed

1

Research Sites

1728 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study is a prospective, noninteractive, observational, and longitudinal study aimed at assessing the treatment pattern and clinical outcome of acromegaly in China.

CONDITIONS

Official Title

The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Able and willing to sign the informed consent form
  • Male or female aged 18 to 75 years old (including 18 and 75)
  • Diagnosed with acromegaly confirmed by at least one random growth hormone measurement ≥ 2.5 µg/L
  • Radiographic evidence of a pituitary tumor shown in at least one medical record or checklist
Not Eligible

You will not qualify if you...

  • Ectopic secretion of growth hormone or pituitary cancer
  • Diagnosed with other malignancies or having residual lesions from previous cancers
  • Having severe acute or chronic medical or psychiatric conditions that increase study risks or interfere with study results
  • Considered inappropriate for enrollment by the Investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

China Acromegaly Organization

Guangzhou, Guangdong, China, 510000

Actively Recruiting

Loading map...

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here